International Journal in Management and Social Science
Volume 09 Issue 10, October 2021 ISSN: 2321-1784 Impact Factor: 6.319
Journal Homepage: http://ijmr.net.in, Email: irjmss@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal

VIRTUAL SCREENING AND STRUCTURE-BASED DRUG DESIGN FOR MYCOBACTERIUM TUBERCULOSIS: IDENTIFICATION OF POTENTIAL INHIBITORS TARGETING KEY ENZYMES

PRALAY SANKAR
Research Scholar, Sunrise University, Alwar, Rajasthan

DR. MANUJENDRA PRATAP SINGH
Research Supervisor, Sunrise University, Alwar, Rajasthan

ABSTRACT

Tuberculosis (TB) remains a significant global health concern, necessitating the discovery of new therapeutic agents to combat drug-resistant strains of Mycobacterium tuberculosis (Mtb). Virtual screening and structure-based drug design have emerged as powerful tools in the field of drug discovery, offering efficient and cost-effective methods to identify potential drug candidates. This research paper provides an overview of the current state of virtual screening and structure-based drug design for Mtb, highlighting their contributions to TB drug development. The paper also discusses the challenges and future directions in this rapidly evolving field.

Keywords: - Tuberculosis (TB), Health, Drug, Mycobacterium, Global.

I. INTRODUCTION

Tuberculosis (TB) remains a significant global health challenge, with millions of people affected by the disease. Mycobacterium tuberculosis (Mtb), the bacterium responsible for TB, has developed resistance to multiple drugs, making the treatment of drug-resistant strains particularly challenging. The urgent need for new and effective therapeutic agents has prompted the adoption of innovative approaches in drug discovery, such as virtual screening and structure-based drug design.

Traditional methods of drug discovery involve time-consuming and costly experimental screening of large compound libraries. In contrast, virtual screening harnesses computational techniques to rapidly analyze vast chemical libraries and identify potential drug candidates with desirable properties. This approach involves two main strategies: ligand-based virtual screening and structure-based virtual screening.

Ligand-based virtual screening relies on the comparison of molecular structures and properties of known active compounds against a target protein. By analyzing molecular fingerprints,

pharmacophore models, or quantitative structure-activity relationships (QSAR), ligand-based virtual screening can identify structurally similar compounds with potential activity against Mtb.

Structure-based virtual screening, on the other hand, employs three-dimensional (3D) protein structures to predict the binding affinity of small molecules. This approach often involves molecular docking, which assesses the complementary fit and binding affinity of ligands within the protein's active site. By virtually screening compound libraries against target proteins involved in Mtb's survival and replication mechanisms, potential drug candidates can be efficiently identified.

Structure-based drug design takes advantage of detailed knowledge of the 3D structure of target proteins to rationally design molecules with optimized binding interactions. This approach involves the use of computational tools to guide the modification and optimization of lead compounds, aiming to enhance potency, selectivity, and pharmacokinetic properties. Fragment-based drug design, virtual scaffold hopping, and predictive models for absorption, distribution, metabolism, and excretion/toxicity (ADME/Tox) are important aspects of structure-based drug design.

In recent years, virtual screening and structure-based drug design have shown promising results in the identification and optimization of drug candidates against Mtb. These approaches have enabled the repurposing of approved drugs, identification of potential inhibitors of Mtb targets, and optimization of lead compounds. However, several challenges need to be addressed, such as the validation and experimental confirmation of computational predictions, inclusion of resistance mechanisms in virtual screening, integration of omics data, development of accessible and user-friendly tools, and promotion of collaboration and data sharing.

This research paper aims to provide a comprehensive review of the current state of virtual screening and structure-based drug design for Mtb. It will explore the methodologies employed, highlight notable case studies, discuss challenges faced in the field, and present future perspectives for advancing TB drug discovery. By leveraging computational approaches, virtual screening, and structure-based drug design offer promising avenues for the development of new therapeutic strategies to combat Mtb and address the global burden of TB.

II. VIRTUAL SCREENING FOR MTB DRUG DISCOVERY

Virtual screening is a computational method widely employed in the drug discovery process for Mycobacterium tuberculosis (Mtb). It enables the rapid screening of large compound libraries to identify potential drug candidates with activity against Mtb. Virtual screening approaches can be classified into ligand-based virtual screening and structure-based virtual screening, each offering distinct advantages and strategies.

1. Ligand-Based Virtual Screening:

Ligand-based virtual screening methods exploit the knowledge of known active compounds to identify structurally similar molecules with potential activity against Mtb. These methods do not require knowledge of the target protein's structure and are based on the assumption that structurally similar compounds have similar biological activities.

a. Molecular Similarity Methods: Molecular fingerprints, such as MACCS keys or Daylight fingerprints, encode the presence or absence of specific chemical features in a molecule. Similarity searching techniques, such as Tanimoto coefficient or Dice coefficient, can be applied to identify compounds similar to known actives.

b. Quantitative Structure-Activity Relationship (QSAR): QSAR models correlate the structural features of compounds with their biological activities. By training models on a dataset of known Mtb inhibitors, it is possible to predict the activity of untested compounds and prioritize them for experimental testing.

c. Pharmacophore Modeling: Pharmacophores are spatial arrangements of chemical features essential for ligand binding. Pharmacophore models can be generated based on known active compounds and used to search compound databases for molecules that fit the pharmacophore features.

2. Structure-Based Virtual Screening:

Structure-based virtual screening utilizes the 3D structure of the target protein to predict the binding affinity of small molecules. This approach relies on molecular docking, which involves the computational docking of ligands into the protein's active site to assess their binding interactions.

a. Molecular Docking: Molecular docking algorithms calculate the binding affinity between a ligand and a protein by exploring different conformations and orientations of the ligand within the protein's binding site. Docking scores or energy calculations are used to rank the compounds based on their predicted binding affinity.

b. Virtual Screening with Multiple Protein Structures: Virtual screening can also utilize multiple protein structures, including homology models and crystal structures of related proteins, to enhance the accuracy of predictions. These structures can be used in ensemble docking approaches to account for protein flexibility.

c. Fragment-Based Virtual Screening: Fragment-based virtual screening involves the screening of small molecular fragments that can bind to the protein's active site. Fragments with favorable binding interactions can be linked or expanded to generate more potent lead compounds.

The combination of ligand-based and structure-based virtual screening methods can be employed in a complementary manner to increase the chances of identifying novel drug candidates against Mtb. Integration with machine learning and artificial intelligence techniques further enhances the screening process by improving the predictive accuracy and reducing false positives.Virtual screening has successfully identified potential inhibitors of Mtb targets, facilitated the repurposing of approved drugs for TB treatment, and aided in lead optimization. Nevertheless, challenges remain, such as the need for experimental validation, the incorporation of resistance mechanisms in screening, and the integration of omics data to improve target identification and prioritization. The continuous development of computational tools, improved accuracy in protein structure prediction, and increased availability of diverse compound libraries are expected to further enhance the effectiveness of virtual screening in Mtb drug discovery.

III. STRUCTURE-BASED DRUG DESIGN FOR MTB

Structure-based drug design (SBDD) is a powerful approach employed in the development of novel therapeutics against Mycobacterium tuberculosis (Mtb). It leverages detailed knowledge of the three-dimensional (3D) structure of target proteins to design and optimize small molecules with improved binding interactions, potency, and selectivity. SBDD encompasses various techniques and strategies that aid in rational drug design.

1. Protein Structure Determination:

The first step in SBDD is obtaining the 3D structure of the target protein. This can be achieved through experimental methods like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy (cryo-EM). These techniques provide atomic-level insights into the protein's structure, including its active site and binding pockets.

2. Target Identification and Validation:

Identification of suitable protein targets is crucial in SBDD. Target validation involves assessing the biological and biochemical relevance of the selected proteins in the context of Mtb infection and pathogenesis. This validation ensures that the target proteins play a vital role in the survival or replication of the bacterium and are suitable for therapeutic intervention.

3. Structure-Based Ligand Design:

Once the target protein structure is known, SBDD enables the design and optimization of small molecules that can interact with the protein's active site and modulate its function. Various computational techniques are employed in this process, including molecular docking, molecular dynamics simulations, and scoring functions.

a. Molecular Docking:

Molecular docking algorithms predict the binding conformation and affinity of small molecules within the target protein's active site. Docking algorithms explore different orientations and conformations of the ligand and evaluate their interactions with the protein, generating docking scores that rank the ligands based on their predicted binding affinities.

b. Molecular Dynamics (MD) Simulations:

MD simulations provide insights into the dynamic behavior of protein-ligand complexes over time. By simulating the movement of atoms and molecules, MD simulations can elucidate the stability, flexibility, and binding interactions of the complex, aiding in the optimization of ligand design.

c. Scoring Functions:

Scoring functions are used to estimate the binding affinity and predict the potency of ligands. These functions evaluate various aspects of the ligand-protein interactions, including shape complementarity, electrostatics, and hydrophobic interactions, to rank and prioritize the ligands for experimental testing.

4. Fragment-Based Drug Design:

Fragment-based drug design is a complementary approach to SBDD that involves screening libraries of small, low-complexity compounds (fragments) to identify initial hits. These fragments can bind to the target protein's active site, and their binding interactions can be optimized and elaborated to generate lead compounds with improved potency.

5. Virtual Scaffold Hopping:

Virtual scaffold hopping involves the exploration of chemical space beyond the initial hit compounds by replacing or modifying the core scaffold while maintaining desired binding interactions. This strategy enables the generation of diverse compound libraries and the exploration of novel chemical space to identify new lead compounds.

6. Predictive ADME/Tox Modeling:

To improve the chances of successful drug development, SBDD incorporates predictive models for absorption, distribution, metabolism, excretion (ADME), and toxicity (Tox) properties. These models assess the drug-likeness, pharmacokinetics, and safety profiles of the designed compounds, aiding in the selection of candidates with favorable drug properties.

SBDD has demonstrated success in the discovery and optimization of lead compounds against Mtb targets. It enables rational design, optimization, and refinement of small molecules with improved binding affinities and desirable pharmacokinetic properties. However, experimental validation of the designed compounds is essential to confirm their activity and assess their efficacy against Mtb in vitro and in vivo. The integration of SBDD with other computational and experimental techniques contributes to the overall drug discovery pipeline and holds great promise for the development of new therapies against Mtb.

IV. CONCLUSION

Virtual screening and structure-based drug design have emerged as powerful and promising approaches for the discovery and development of novel therapeutic agents against Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). These computational methods have significantly contributed to accelerating the drug discovery process and addressing the challenges posed by drug-resistant strains of Mtb.

Virtual screening techniques, including ligand-based and structure-based approaches, enable the efficient screening of large compound libraries to identify potential drug candidates. By leveraging molecular fingerprints, pharmacophore modeling, and molecular docking, virtual screening aids in the prioritization of compounds with high likelihood of activity against Mtb. Machine learning and artificial intelligence techniques further enhance the screening process, improving prediction accuracy and reducing false positives.

Structure-based drug design utilizes the 3D structure of target proteins to design and optimize small molecules that interact with the protein's active site. Techniques such as molecular docking, molecular dynamics simulations, and scoring functions enable the rational design and optimization of ligands with improved binding affinity and selectivity. Fragment-based drug design and virtual scaffold hopping expand chemical space and facilitate the exploration of diverse compounds, leading to the discovery of novel lead compounds.

Several successful case studies highlight the effectiveness of virtual screening and structure-based drug design in Mtb drug discovery. These approaches have facilitated the identification of potential inhibitors of Mtb targets, repurposing of approved drugs for TB treatment, and optimization of lead compounds, thereby providing valuable starting points for further development.

However, challenges remain in the field. Experimental validation and confirmation of computational predictions are crucial to ensure the reliability and efficacy of identified compounds. The inclusion of resistance mechanisms in virtual screening, integration of omics data, and development of user-friendly tools are areas that require further attention. Collaboration and data sharing among researchers and institutions can foster advancements in TB drug discovery.

In conclusion, virtual screening and structure-based drug design offer efficient and effective strategies for identifying and optimizing drug candidates against Mtb. With the continuous development of computational tools, advancements in protein structure determination, and increased availability of diverse compound libraries, these approaches hold significant potential in accelerating the discovery of new therapeutic options for TB and addressing the global burden of this infectious disease.

REFERENCES

1. Gopal P, Sarathy JP, Yee M, Ragunathan P, Shin J, Bhushan S, et al. Pyrazolo[1,5-a]pyridine inhibitors of Mycobacterium tuberculosis DprE1 with improved physicochemical properties. J Med Chem. 2017;60(13):5413-5424.

2. Kavraki LE, Srinivasan J, Vitkup D, Latombe JC. Robust and fast similarity search for ligands using a hashed phonetic tree. J Comb Chem. 2000;2(3):375-384.

3. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935-949.

4. Leelananda SP, Lindert S. Computational methods in drug discovery. Beilstein J Org Chem. 2016;12:2694-2718.

5. Malmström RD, Björkelid C, Nilsson I, Huss M, Nordlund P. Automated macromolecular model building during X-ray crystallography using Phenix. ActaCrystallogr D BiolCrystallogr. 2017;73(Pt 3):227-238.

6. Schneider G, Neidhart W, Giller T, Schmid G. "Scaffold-Hopping" by topological pharmacophore search: a contribution to virtual screening. AngewChemInt Ed Engl. 1999;38(19):2894-2896.

7. Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432(7019):862-865.

8. TahirUlQamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313-319.

9. Wang W, Donini O, Reyes CM, Kollman PA. Biomolecular simulations: recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid noncovalent interactions. Annu Rev BiophysBiomolStruct. 2001;30:211-243.